Study of KRAS-Related miRNA Expression in Colorectal Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.21442
   PubMed Web of Science ®Google Scholar
• Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015;33:1809–1824. doi:10.1200/JCO.2014.59.7633
   PubMed Web of Science ®Google Scholar
• Jancik S, Drabek J, Radzioch D, Hajduch M. Clinical relevance of KRAS in human cancers. J Biomedcine Biotechnol. 2010;2010:1–13. doi:10.1155/2010/150960
   Google Scholar
• Fernández-medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2:344–358. doi:10.1177/1947601911411084
   PubMedGoogle Scholar
• Li X, Yang T, Li CS, et al. Surface enhanced Raman spectroscopy (SERS) for the multiplex detection of BRAF, KRAS, and PIK3CA mutations in plasma of colorectal cancer patients. Theranostics. 2018;8:1678–1689. doi:10.7150/thno.22502
   PubMed Web of Science ®Google Scholar
• Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–691. doi:10.1016/j.cell.2016.11.037
   PubMed Web of Science ®Google Scholar
• Chen P, Li X, Zhang R, et al. Combinative treatment of beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. Theranostics. 2020;10:5107–5119. doi:10.7150/thno.44705
   PubMed Web of Science ®Google Scholar
• Choi JW, Kim P, Kim JK, et al. Longitudinal tracing of spontaneous regression and anti-angiogenic response of individual microadenomas during colon tumorigenesis. Theranostics. 2015;5:724–732. doi:10.7150/thno.10734
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–222. doi:10.1038/nrd.2016.246
   PubMed Web of Science ®Google Scholar
• Cooks T, Pateras IS, Jenkins LM, et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat Commun. 2018;9:771. doi:10.1038/s41467-018-03224-w
   PubMed Web of Science ®Google Scholar
• Yang Y, Shu X, Liu D, et al. EPAC null mutation impairs learning and social interactions via aberrant regulation of miR-124 and ZIF268 translation. Neuron. 2012;73:774–788. doi:10.1016/j.neuron.2012.02.003
   PubMed Web of Science ®Google Scholar
• Chu PC, Lin P-C, Wu H-Y, et al. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. Oncogene. 2018;37:3440–3455. doi:10.1038/s41388-018-0222-3
   PubMed Web of Science ®Google Scholar
• Masciarelli S, Fontemaggi G, Di Agostino S, et al. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene. 2014;33:1601–1608. doi:10.1038/onc.2013.106
   PubMed Web of Science ®Google Scholar
• Prossomariti A, Piazzi G, D’Angelo L, et al. MiR-155 is downregulated in familial adenomatous polyposis and modulates WNT signaling by targeting AXIN1 and TCF4. Mol Cancer Res. 2018;16:1965–1976. doi:10.1158/1541-7786.MCR-18-0115
   PubMed Web of Science ®Google Scholar
• De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpa RS. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12:594–603. doi:10.1016/S1470-2045(10)70209-6
   PubMed Web of Science ®Google Scholar
• Mamoori A, Wahab R, Islam F, et al. Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis. Hum Pathol. 2018;71:145–156. doi:10.1016/j.humpath.2017.10.024
   PubMed Web of Science ®Google Scholar
• Fan Q, Hu X, Zhang H, et al. MiR-193a-3p is an important tumour suppressor in lung cancer and directly targets KRAS. Cell Physiol Biochem. 2017;44:1311–1324. doi:10.1159/000485491
   PubMedGoogle Scholar
• Amankwatia EB, Chakravarty P, Carey FA, et al. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Br J Cancer. 2015;112:1480–1490. doi:10.1038/bjc.2015.125
   PubMed Web of Science ®Google Scholar
• Chen X, Guo X, Zhang H, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009;28:1385–1392. doi:10.1038/onc.2008.474
   PubMed Web of Science ®Google Scholar
• Akao Y, Kumazaki M, Shinohara H, et al. Impairment of KRas signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. Cancer Sci. 2018;109:1–13. doi:10.1111/cas.13559
   PubMed Web of Science ®Google Scholar
• Hara T, Jones MF, Subramanian M, et al. Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells. Oncotarget. 2014;5:7635–7650. doi:10.18632/oncotarget.2284
   PubMedGoogle Scholar
• Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012;12:505. doi:10.1186/1471-2407-12-505
   PubMed Web of Science ®Google Scholar
• Pugh S, Thiébaut R, Bridgewater J, et al. Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. Oncotarget. 2017;8:93856–93866. doi:10.18632/oncotarget.21291
   PubMedGoogle Scholar
• Ramon L, David C, Fontaine K, et al. Technical validation of a reverse-transcription quantitative polymerase chain reaction in vitro diagnostic test for the determination of MiR-31-3p expression levels in formalin-fixed paraffinembedded metastatic colorectal cancer tumor specimens. Biomark Insights. 2018;13:1–11. doi:10.1177/1177271918763357
   Web of Science ®Google Scholar
• Manceau G, Imbeaud S, Thiébaut R, et al. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res. 2014;20:3338–3347. doi:10.1158/1078-0432.CCR-13-2750
   PubMed Web of Science ®Google Scholar
• Wu X, Xu X, Li S, et al. Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. PLoS One. 2015;10:e0120024. doi:10.1371/journal.pone.0120024
   PubMed Web of Science ®Google Scholar
• Wu X, Li S, Xu X, et al. The potential value of miR-1 and miR-374b as biomarkers for colorectal cancer. Int J Clin Exp Pathol. 2015;8:2840–2851.
   PubMed Web of Science ®Google Scholar
• Livak K, Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25:402–408. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008;36:D154–D158. doi:10.1093/nar/gkm952
   PubMed Web of Science ®Google Scholar
• Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature. 2009;460:529–533. doi:10.1038/nature08199
   PubMed Web of Science ®Google Scholar
• Lin PL, Wu D-W, Huang -C-C, et al. MicroRNA-21 promotes tumour malignancy via increased nuclear translocation of beta-catenin and predicts poor outcome in APC-mutated but not in APC-wild-type colorectal cancer. Carcinogenesis. 2014;35:2175–2182. doi:10.1093/carcin/bgu110
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol. 2013;31:1112–1121. doi:10.1200/JCO.2012.43.0454
   PubMed Web of Science ®Google Scholar
• Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev. 2010;31:31–38.
   PubMedGoogle Scholar
• Lièvre A, Bachet J-B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995. doi:10.1158/0008-5472
   PubMed Web of Science ®Google Scholar
• Ung L, Lam AK, Morris DL, Chua TC. Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review. Clin Transl Oncol. 2014;16:425–435. doi:10.1007/s12094-013-1154-6
   PubMed Web of Science ®Google Scholar
• Sameen S, Barbuti R, Milazzo P, et al. Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. J Theor Biol. 2016;389:263–273. doi:10.1016/j.jtbi.2015.10.019
   PubMed Web of Science ®Google Scholar
• Osumi H, Shinozaki E, Osako M, et al. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Mol Clin Oncol. 2015;3:1053–1057. doi:10.3892/mco.2015.602
   PubMedGoogle Scholar
• Langsch S, Baumgartner U, Haemmig S, et al. MiR-29b mediates NF-kappaB signaling in KRAS-induced non-small cell lung cancers. Cancer Res. 2016;76:4160–4169. doi:10.1158/0008-5472.CAN-15-2580
   PubMed Web of Science ®Google Scholar
• Yuan P, He X-H, Rong Y-F, et al. KRAS/NF-kappaB/YY1/miR-489 signaling axis controls pancreatic cancer metastasis. Cancer Res. 2017;77:100–111. doi:10.1158/0008-5472.CAN-16-1898
   PubMed Web of Science ®Google Scholar
• Xu XH, Wu X-B, Wu S-B, et al. Identification of miRNAs differentially expressed in clinical stages of human colorectal carcinoma-an investigation in Guangzhou, China. PLoS One. 2014;9:e94060. doi:10.1371/journal.pone.0094060
   PubMed Web of Science ®Google Scholar
• Luo Y, Yu S-Y, Chen -J-J, et al. MiR-27b directly targets Rab3D to inhibit the malignant phenotype in colorectal cancer. Oncotarget. 2017;9:3830–3841. doi:10.18632/oncotarget.23237
   PubMedGoogle Scholar
• Ge T, Xiang P, Mao H, et al. Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1. Exp Ther Med. 2020;20:2134–2140. doi:10.3892/etm.2020.8936
   PubMed Web of Science ®Google Scholar
• Han Y, Zhao Q, Zhou J, Shi R. miR-429 mediates tumor growth and metastasis in colorectal cancer. Am J Cancer Res. 2017;7:218–233.
   PubMed Web of Science ®Google Scholar
• Guo F, Luo Y, Mu Y-F, et al. miR-193b directly targets STMN1 and inhibits the malignant phenotype in colorectal cancer. Am J Cancer Res. 2016;6:2463–2475.
   PubMed Web of Science ®Google Scholar
• Tian X, Chang J, Zhang N, Wu S, Liu H, Yu J. MicroRNA-429 acts as a tumor suppressor in colorectal cancer by targeting high mobility group box 3. Oncol Lett. 2021;21:250. doi:10.3892/ol.2021.12511
   PubMed Web of Science ®Google Scholar